Abliva

Bergs Securities acted as sole global coordinator and bookrunner in the SEK 46m rights issue and the SEK 42m private placement of convertible debentetures in Abliva.

Abliva develops medicines for the treatment of mitochondrial disease. This congenital, rare and often very severe disease occurs when the cell’s energy provider, the mitochondria, do not function properly. The portfolio includes projects at different stages and ranges from early discovery phase to clinical phase.